✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

If you have been on Truvada (TDF/FTC) for HIV pre-exposure prophylaxis for a while, you may have asked your clinician about switching to Descovy (TAF/FTC). The two products contain the same emtricitabine partner and protect against HIV with the same efficacy in eligible populations — but the tenofovir prodrug differs, and that difference matters most for your kidneys and bones. The switch is not automatic: it makes sense for some people, not for others, and the cost calculus has shifted significantly with generic TDF/FTC and looming generic TAF/FTC.

This guide walks through why people switch, the specific renal and bone markers worth retesting around the transition, the timing logistics (no washout needed), the populations where Descovy is not the right choice regardless of TDF tolerability, and the practical cost framework for making the decision.

Switching from Truvada to Descovy: Why People Switch, Renal Markers to Retest & Timing

Reviewed by Morgan Ellis, Clinical Pharmacy Editor — MedsBase Medical Review Team. Last updated: 16 May 2026.

Quick Answer: Should You Switch?

Switch to Descovy (TAF/FTC) if you have measurable renal or bone changes on TDF/FTC — eGFR declining, low bone mineral density, or cumulative TDF exposure of 5+ years with concerning trends. Stay on Truvada generics (TDF/FTC) if you have stable kidneys and bones, are a cisgender woman, are using 2-1-1 on-demand PrEP, or if cost is decisive. No washout needed; retest eGFR, urinary protein, serum phosphate, and lipids at 3 months post-switch.

What’s Actually Different Between Truvada and Descovy

The two PrEP medications share the emtricitabine (FTC) component but differ in the tenofovir prodrug:

• Truvada contains tenofovir disoproxil fumarate (TDF) 300 mg + FTC 200 mg.
• Descovy contains tenofovir alafenamide (TAF) 25 mg + FTC 200 mg.

TDF and TAF are different prodrugs that deliver the same active tenofovir to target cells via different routes. TDF is converted to tenofovir primarily in plasma — the active drug then has to circulate at high systemic levels to reach lymphoid cells, exposing the kidneys and bones to peripheral drug concentrations along the way. TAF is metabolised primarily inside target cells, where it is cleaved to tenofovir at the site of action — producing higher intracellular tenofovir-diphosphate concentrations at a much lower oral dose (25 mg vs 300 mg) and dramatically lower peripheral plasma concentrations.

The pharmacokinetic consequence: TAF produces about one-fifth to one-tenth of the plasma tenofovir exposure that TDF produces, while maintaining or exceeding intracellular concentrations needed for HIV inhibition. The clinical consequences:

• Renal function — TAF causes smaller eGFR declines and less proteinuria than TDF over time.
• Bone mineral density — TAF causes smaller BMD declines (typically 1 to 2% less loss at lumbar spine and hip compared to TDF over 48 weeks).
• Lipids — TAF tends to raise LDL and HDL modestly (a few mg/dL each, net cardiovascular effect uncertain).
• Weight — TAF users gain slightly more weight than TDF users (mean difference of 1 to 2 kg over the first year; mechanism not fully understood).

For PrEP specifically, HIV protection efficacy is equivalent between TDF/FTC and TAF/FTC in studied populations.

Why People Switch: Specific Indications

1. Progressive eGFR decline

The most common reason. TDF causes proximal tubule dysfunction in a subset of users — sometimes subclinical, sometimes progressing to Fanconi syndrome (proteinuria, hypophosphatemia, glycosuria, acidosis). For users showing eGFR decline of 5 to 10 mL/min/1.73m² from baseline, particularly with rising creatinine or new proteinuria, switching to TAF is reasonable.

Thresholds where switching becomes strongly recommended:

• eGFR falling below 60 mL/min/1.73m² from a previously normal baseline.
• New-onset proteinuria (urinary protein-to-creatinine ratio >0.2).
• Falling serum phosphate (a marker of proximal tubule dysfunction, even at normal eGFR).
• Glycosuria without diabetes (also a Fanconi marker).

TDF should be discontinued (switch to TAF or stop PrEP entirely) if eGFR falls below 30 mL/min/1.73m² — TDF is contraindicated below this threshold; TAF can be continued down to 15 mL/min/1.73m² with caution.

2. Low baseline or declining bone mineral density

TDF causes BMD declines of 1 to 3% at lumbar spine and 0.5 to 2% at hip over 48 to 96 weeks of continuous use. For most users with normal pre-PrEP BMD, this is clinically irrelevant. For users with pre-existing low BMD, family history of fragility fractures, postmenopausal status, or long-term steroid use, the additional BMD cost of TDF may push them into osteopenia or osteoporosis range.

DEXA scan threshold for considering TAF:

• Lumbar spine or hip T-score below -1.0 (osteopenia) pre-PrEP.
• Documented decline in T-score during PrEP exceeding what would be expected from age and sex.
• History of fragility fracture during PrEP use.

3. Long cumulative TDF exposure

For users on TDF for 5+ years, cumulative effects on renal and bone tissue accumulate even in the absence of dramatic individual-test changes. The case for switching becomes stronger with each additional year of exposure, particularly above age 50.

4. Age over 50

Older users have less renal reserve and less bone reserve, and the long time horizon of continued PrEP makes cumulative cost reduction more meaningful. For users initiating PrEP at age 50+, TAF is often the better starting choice rather than waiting for TDF problems to develop.

5. Co-existing renal-toxic drug use

Users on chronic NSAIDs, ACE inhibitors, ARBs, or other drugs that contribute to renal stress may benefit from removing the TDF component of that burden by switching to TAF.

6. Side effect tolerance

Some users report GI symptoms, fatigue, or general malaise that improves on TAF — though the placebo-controlled evidence for these subjective effects is weaker than for objective renal and bone markers.

Why People Don’t Switch: Where TDF/FTC Wins

1. Stable renal and bone status

For users who have been on Truvada generics for 1 to 3 years with stable eGFR, no proteinuria, normal phosphate, and normal or near-normal bone density, the marginal benefit of switching is small. The cost difference often wins.

2. Cisgender women

This is the most important contraindication. TAF/FTC has not been adequately studied in cisgender women for PrEP — DISCOVER, the trial that supported FDA approval, did not enrol enough cisgender women or transgender men at risk via receptive vaginal exposure to establish efficacy. The FDA label limits Descovy PrEP to cisgender MSM and transgender women. For cisgender women, only TDF/FTC (Truvada generics, Tenvir-EM, Ricovir-EM) is appropriate for PrEP.

3. 2-1-1 on-demand PrEP users

The event-driven 2-1-1 protocol (2 pills 2 to 24 hours before sex, 1 pill 24 hours after first dose, 1 pill 24 hours after that) was validated in the IPERGAY trial using TDF/FTC only. The pharmacokinetic profile of TAF — different absorption, different intracellular concentration ramp — does not necessarily support the same on-demand dosing schedule, and efficacy data does not exist for 2-1-1 with TAF. Users on 2-1-1 should remain on TDF/FTC. See our missed PrEP dose guide for the broader on-demand context.

4. Cost-decisive users

Generic TDF/FTC is universally cheaper than brand Descovy and even cheaper than international generic TAF/FTC. For users with stable PrEP biomarkers and tight budgets, the cost argument for staying on TDF/FTC is straightforward and reasonable.

5. Established safety record

TDF has been in widespread PrEP use since 2012; TAF since 2019. The longer real-world safety record for TDF is reassuring in a way that TAF cannot match for several more years. For users who weight published-data confidence highly, this matters.

The Switch Itself: No Washout, Direct Transition

The mechanical part of switching is simple. There is no washout period required, no overlap, no titration:

• Day N: last dose of TDF/FTC (Truvada generic, Tenvir-EM, or Ricovir-EM).
• Day N+1: first dose of TAF/FTC (Descovy or Taficita).
• Continuity of HIV protection is maintained — both drugs target the same viral process at the same intracellular site.

If you have been adherent on TDF/FTC and you take TAF/FTC the next day, protection is uninterrupted.

Adherence reset

The switch is a natural moment to reset adherence habits. If you have been on TDF for years with imperfect adherence (occasional missed doses), the cleaner start on TAF is an opportunity to recommit to consistent daily dosing — particularly because PrEP efficacy is highly adherence-dependent.

What to Retest and When

Baseline (immediately before the switch)

Document the markers you will track afterward:

• HIV antibody / antigen test (always — confirm HIV-negative status before any PrEP regimen change).
• eGFR via serum creatinine.
• Urinary protein-to-creatinine ratio (UPCR) — most sensitive marker of proximal tubule dysfunction.
• Serum phosphate.
• Lipid panel (LDL, HDL, triglycerides).
• STI screen (HIV, syphilis, gonorrhea, chlamydia).
• Hepatitis B status (essential — HBV reactivation risk if PrEP is later discontinued).
• DEXA scan if pre-existing risk factors for low BMD.

3 months post-switch

Repeat the kidney and metabolic markers:

• eGFR.
• Urinary protein-to-creatinine ratio.
• Serum phosphate.
• Lipid panel (note TAF tends to raise LDL and HDL by a few mg/dL each).
• Quarterly STI screen per standard PrEP protocol.

6 to 12 months post-switch

• Confirm renal and metabolic markers are stable on TAF.
• Repeat DEXA at 12 to 24 months if baseline was abnormal.
• Continue quarterly STI / HIV monitoring.

What to expect on the markers

• eGFR — should stabilise or modestly improve; substantial improvement is not expected if baseline decline was minor.
• UPCR — should normalise within 3 to 6 months if TDF-driven proteinuria was present.
• Serum phosphate — should normalise within 3 months if it had fallen on TDF.
• Lipids — LDL and HDL typically rise by a few mg/dL on TAF; clinical significance is uncertain but worth tracking, particularly in users with pre-existing cardiovascular risk factors.
• Weight — modest gain of 1 to 2 kg over the first year is common on TAF; mechanism unclear, response uncertain.
• BMD — declines on TDF generally do not reverse on TAF, but progression slows. Newly initiated baseline BMD typically improves modestly over 24 months.

Cost Calculus: Generic TDF/FTC vs Brand Descovy vs International Generic TAF/FTC

The pricing reflects approximate market conditions; actual cost varies with formulary, supplier, region, manufacturer assistance programs, and insurance status. For ongoing context on the generic Descovy timeline see our generic Descovy patent expiry guide and for sourcing context see buying PrEP online.

Special Situations

Active hepatitis B coinfection

Both TDF and TAF are active against hepatitis B virus, but the formulations and dosing schedules differ from PrEP regimens. Patients with active HBV require coordinated planning before any PrEP regimen change — abrupt discontinuation of either prodrug can trigger HBV reactivation and severe hepatitis flare. Hepatitis B status must be known before initiating, modifying, or discontinuing any tenofovir-containing PrEP.

Pregnancy

TDF is generally considered safe during pregnancy with the longest safety record. TAF data in pregnancy is sparser; safety appears similar but documentation is more limited. For users planning pregnancy or actively pregnant, TDF is the better-characterised choice.

Renal transplant or chronic kidney disease

TAF is preferred over TDF for users with established chronic kidney disease (eGFR 30 to 60). TDF is contraindicated below eGFR 30; TAF can be continued down to eGFR 15 with caution.

Switch failure or regret

If TAF causes unexpected side effects (lipid changes, weight gain, GI), switching back to TDF/FTC is straightforward — same direct-transition logic, no washout needed. Some users alternate based on annual biomarker patterns.

Sourcing Considerations

For users sourcing PrEP outside the brand market, three quality signals matter:

1. WHO-GMP certification

Reputable manufacturers (Cipla, Hetero, Mylan, Aurochem) publish facility registrations and inspection records. WHO-GMP certification is the minimum quality bar for generic PrEP supply.

2. Active ingredient identity verification

The blister packaging, tablet markings, and lot numbers should match the manufacturer’s published specifications. A Certificate of Analysis per lot is standard for premium suppliers.

3. Cold-chain (low relevance for tablets)

Unlike injectable medications, oral PrEP tablets are stable at room temperature and do not require cold-chain shipping. Reputable suppliers still use appropriate humidity protection.

Verified PrEP options at MedsBase: Tenvir-EM (Cipla TDF/FTC), Ricovir-EM (Hetero TDF/FTC), Taficita (Hetero TAF/FTC — the international generic Descovy equivalent), Tavin-EM (alternative TDF/FTC generic), Tenvir AF (TAF monotherapy, used for hepatitis B rather than PrEP), and the PrEP Starter Pack with Doxy-PEP. For broader sourcing context see buying PrEP online.

Frequently Asked Questions

Do I need a washout period when switching from Truvada to Descovy?

No. The switch is direct — last dose of TDF/FTC on day N, first dose of TAF/FTC on day N+1. Both drugs target the same intracellular HIV replication process, so protection continuity is maintained without overlap.

Will my eGFR improve after switching?

If your eGFR was declining on TDF, the decline should stabilise within 1 to 3 months of switching to TAF. Modest improvement may occur but is not guaranteed — significant pre-switch decline may not fully reverse. The benefit is preventing further decline, not necessarily reversing existing damage.

How quickly will proteinuria resolve?

TDF-induced proteinuria (elevated urinary protein-to-creatinine ratio) typically resolves within 3 to 6 months of switching to TAF. If proteinuria persists beyond 6 months, evaluate for non-TDF causes (hypertension, diabetes, glomerular disease).

Should I switch if I am asymptomatic and my labs are stable?

The marginal benefit is small. For users with stable eGFR, normal proteinuria, normal phosphate, normal BMD, and no other risk factors, the cost of brand Descovy is rarely justified by the modest projected renal and bone benefit. International generic TAF/FTC changes the calculation by removing the cost barrier — but the clinical case for switching is still modest in this scenario.

I’m a cisgender woman on Truvada — should I switch to Descovy?

No. TAF/FTC is not approved for PrEP in cisgender women because the DISCOVER trial did not establish efficacy for receptive vaginal exposure. Cisgender women should remain on TDF/FTC (Truvada generics, Tenvir-EM, or Ricovir-EM) for PrEP regardless of TDF tolerability.

I use 2-1-1 on-demand PrEP — can I switch?

No. The 2-1-1 on-demand protocol is validated only with TDF/FTC. TAF pharmacokinetics may not support event-driven dosing the same way, and no efficacy data exists for 2-1-1 with TAF. Stay on TDF/FTC for on-demand PrEP.

Will Descovy cost go down after generic launch?

Yes, eventually. Generic TAF/FTC from WHO-GMP-certified international manufacturers (Hetero’s Taficita) has been available outside the US for several years at roughly 95% lower cost than brand. The US generic Descovy launch is expected in 2026 to 2028 once Gilead’s secondary patents fully expire or are invalidated. The price gap that justifies the brand Descovy premium is closing.

Does switching to Descovy affect HIV testing or STI testing schedule?

No. The switch does not change the standard PrEP monitoring cadence: quarterly HIV testing, quarterly STI screen (gonorrhea, chlamydia, syphilis), renal function at baseline and every 6 to 12 months, hepatitis testing at baseline. The switch is a good moment to confirm the schedule is being followed.

What about long-acting injectable cabotegravir (Apretude) — should I consider it instead of switching to Descovy?

Long-acting injectable cabotegravir is a fundamentally different PrEP approach — an intramuscular injection every 2 months rather than a daily oral pill. It is FDA-approved for PrEP (December 2021) and avoids the renal and bone considerations of oral TDF and TAF entirely. Trade-offs: higher cost, requires consistent clinic visits for injection, and a different long-acting tail to consider when stopping. For users primarily switching to escape TDF kidney effects, Apretude is a reasonable alternative to Descovy.

Can I switch back to Truvada if Descovy doesn’t suit me?

Yes, with the same direct-transition logic. If TAF causes unwanted side effects (weight gain, lipid changes, GI), you can switch back to TDF/FTC on the next dose — no washout, no transition pills. The choice is reversible and revisable.

The Bottom Line

Switching from Truvada to Descovy is reasonable for users with measurable renal or bone changes on TDF/FTC, cumulative long-term TDF exposure, or pre-existing risk factors that make the marginal TAF benefit meaningful. It is not the right move for users with stable kidneys and bones, cisgender women, 2-1-1 on-demand users, or cost-decisive users while the brand-Descovy price gap persists.

The switch itself is simple — no washout, direct transition, continuous protection. The retest schedule at 3 months (eGFR, UPCR, phosphate, lipids) and at 12 to 24 months (DEXA if relevant) catches the benefits and any unintended consequences of the swap. The cost calculus shifts every year as generic TAF/FTC becomes more available — keep the decision under review as the market evolves.

For ongoing supply and product details see our verified PrEP options: Tenvir-EM, Ricovir-EM, Taficita, Tavin-EM, Tenvir AF, and the PrEP Starter Pack. Related reading: Truvada vs Descovy molecule comparison, generic Descovy patent expiry, missed PrEP dose protocols, PrEP side effects in the first 90 days, PrEP STI testing schedule, buying PrEP online, and the what is PrEP primer.

Every order is covered by our Reshipment Assurance Policy: if your parcel does not arrive within 20 business days of dispatch (EMS or ITPS), we send a replacement at no extra cost.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.